Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 16, Issue 9, Pages 1343-1353Publisher
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2010.03334.x
Keywords
5-Fluorocytosine; amphotericin B deoxycholate; anidulafungin; caspofungin; fluconazole; intraconazole; lipid formulations of amphotericin B; micafungin; posaconazole; review; voriconazole
Categories
Funding
- Gilead Sciences
- Merck Co.
Ask authors/readers for more resources
P>Paediatric age groups display important differences in host biology, predisposing conditions, epidemiology and presentation of fungal infections relative to the adult population. During the past decade, several new antifungal agents have been developed. Although not all of these agents are yet approved for children, the paediatric development of antifungal agents has moved forwards in an exemplary manner. Invasive fungal infections will remain important causes of morbidity and mortality in immunocompromised paediatric patients. Whereas the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex, and a thorough understanding of the available antifungal armamentarium is essential for the successful management of the individual patient. This article provides an update on the pharmacokinetics, safety and dosing of antifungal agents in paediatric patients, and their clinical indications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available